



Prostate
Cancer
Foundation

ADVANCES

A Monthly Update from the CEO

Jonathan W. Simons, MD – jsimons@pcf.org

September 2008



An Eternal Verity: Young Investigators

Dr. Charles Huggins was pithy in speech, and wrote concise research reports with the philosophy that “less is more.” When it comes to youth in cancer research, I believe he said it best in the late 1960s: “I believe in three things: young people, hard work, and finding cures for cancer.”

Huggins was an authority on young investigators. He was a urologist-scientist at the University of Chicago and won the Nobel Prize for discovering that prostate cancer and breast cancer were dependent on hormones. He surrounded himself with brilliant students who assisted him in all the key experimentation leading to his Nobel Prize. (A great source of information on Huggins is <http://www.uchospitals.edu/news/1997/19970113-huggins.html>.)



Dr. Charles Huggins

I was introduced to Dr. Huggins at Johns Hopkins almost thirty years later by my own mentor, Dr. Donald Coffey. Huggins felt Coffey was a spiritual disciple—a research director for a new generation. He encouraged Coffey constantly to mentor unselfishly. Huggins was ninety when I met him. He was elderly but intellectually incisive. As a young investigator myself (with my first CaPCure and NCI “K” Physician Scientist Awards), I asked him what advice he had for young investigators in 1995. Huggins smiled and said, “Enjoy the unfettered arrogance of youth in your own experiments, and surround yourself with young people doing unfettered experiments when you find you are not so young any more.”

Coffey later explained to me that whenever Huggins traveled, he always spent more time with postdoctoral fellows and junior faculty than senior faculty. He learned more that way.

This September I was privileged to be with many young investigators. And I am pleased to report that their talent, optimism and unfettered arrogance are alive and well.

During the month, I visited Stanford University's Cancer Nanotechnology Center, Memorial Sloan-Kettering Cancer Center, the University of California at San Francisco, the University of Pennsylvania and Georgia Tech. I had to give research seminars as a visiting professor or attend research meetings, fulfilling commitments that I made prior to taking my current position. In addition, I spent a day at Johns Hopkins with PCF board member Chris Evensen evaluating the progress of our \$5 million PCF Safeway Thermal Enhanced Metastatic Therapy Program, meeting with postdoctoral researchers and former students.

During these visits, I had the occasion to talk about science and clinical research with 14 graduate students, 11 postdoctoral researchers, and five assistant professors. In these discussions I observed four things. First, more women with Ph.D. and M.D., Ph.D. credentials are working on prostate cancer in laboratories than ever before. Why? It's because of their fathers' experience with the disease or, in some cases, because prostate cancer poses some of the most intellectually challenging problems in cancer biology.

Secondly, more than half of those with whom I met were native Chinese or Hindi speakers before they learned English. Thirdly, all are realistic that more meritorious research ideas exist now than can be funded—dozens of *unemployed research ideas* languish at every major academic center. In fact, every major cancer center has a Depression-era *Hooverville* of unfunded, yet creative and ingenious ideas right now. Yet, all I met were optimistic about their own contributions ahead. Finally, almost everyone perceives attaining PCF funding at some point in their career as a prestigious achievement.



Academic cancer research centers have become virtual *Hoovervilles* with unemployed research ideas for prostate cancer. Since 2001, government funding for cancer research has declined 19 percent.

The fight against prostate cancer requires more than just funding advanced research projects. In an environment where the number of exceptionally-trained, highly educated individuals who choose to enter the field of science and technology is dwindling, ensuring a pipeline of talent that will continue advancing the cause is crucial. Thus, human capital for research is our most precious asset.

Nurturing and perpetuating promising careers has become the most difficult of our many challenges in the current funding environment. The PCF's *Young Investigators Awards* program keeps the field of prostate cancer research vibrant with new ideas by identifying future research leaders who are in their thirties. These \$225,000 awards provide three years of career and project support for young (generally 35 and under), proven investigators who have already achieved junior faculty positions and committed their lives to the field of prostate cancer. Each *Young Investigator* is required to have an accomplished and committed mentor; the dollar amount is matched by host institutions. We are impressed by their exceptional dedication to the field and the ingenuity of their research proposals.

“Enjoy the unfettered arrogance of youth in your own experiments, and surround yourself with young people doing unfettered experiments when you find you are not so young any more.”

-- Dr. Charles Huggins

The response to our first year's call for applicants was global, producing 76 applications from eight countries in North America, Europe and Asia. The research proposals covered 16 different areas of prostate cancer research. The applicants represented seven medical and scientific disciplines including; medical oncology, radiation oncology, urology, pathology, imaging science and many areas of molecular science. The response was gratifying.

Now, in a fitting capstone to September's activities, I am able to write about the inaugural class of PCF *Young Investigators*. You cannot imagine my pleasure to share with you the backgrounds of these 19 young investigators and the patrons who are supporting them.

Patron—if you look it up in the *Oxford English Dictionary*—is derived from the Latin word “*patronus*.” *Patronus* means more than “father figure.” It connotes protector, defender and advocate as a part of the support. So our patrons of PCF *Young Investigators* are advocates and defenders of creative, young cancer scientists. In the current funding climate for research, our patrons of *Young Investigators* are to prostate cancer research, as the Medici's were to Florentine artisans and craftsmen: defenders and advocates of the truly gifted who are emerging into greatness.

The Goergen Foundation - PCF Young Investigator

Andrew Armstrong, M.D., Sc.M.

Duke University - Durham, North Carolina



Dr. Armstrong earned a BS in Biomedical Engineering from Duke University, an M.D. degree from the University of Virginia and an M.S. in Clinical Investigation from Johns Hopkins University. He completed a Medical Oncology Fellowship at Johns Hopkins University and is currently an Assistant Professor of Medicine and Surgery at Duke University.

Dr. Armstrong's program focuses on discovering biomarkers that will identify patients with prostate cancer who are at higher risk for a more aggressive clinical progression of the disease. Molecular markers to predict metastasis will be studied on circulating tumor cells – the small proportion of prostate cancer cells that "break away" from the primary cancer and enter blood circulation. Patients presenting these markers might be treated aggressively at an earlier stage of disease.

Daniel George, M.D., and Mariano Garcia-Blanco, M.D., Ph.D., will be mentors for Dr. Armstrong. Dr. George is a genitourinary medical oncologist who leads clinical research in prostate cancer at Duke. Dr. Garcia-Blanco is an RNA biologist whose laboratory is investigating the mechanisms by which prostate cancer cells adapt over time and develop the capacity to metastasize, or spread through the body.

Michael Milken Scholar - PCF Young Investigator

Mohamed S. Arredouani, Ph.D.

Beth Israel Deaconess Hospital - Boston, Massachusetts



Dr. Arredouani earned a BS Degree in Biology from Moulay Ismail University in Morocco, an MS in Molecular Biology from St. Petersburg State Polytechnic University in Russia, and an MS and PhD degrees in Medical Sciences from the Catholic University of Louvain in Belgium. He is currently an instructor in Surgery at the Beth Israel Deaconess Medical Center.

Immunization of patients to generate an immune response to eliminate cancer is an increasingly important therapeutic strategy for advanced prostate cancer. Dr. Arredouani proposes to develop a new generation of prostate cancer vaccines with molecules known to be involved in the malignant transformation of prostate cells. Two such molecules have been selected and will be tested.

Martin Sanda, M.D., an eminent urologic oncologist and cancer research leader in urology at Harvard, will mentor Dr. Arredouani.

The Susan and James Blair - PCF Young Investigator

Gerhardt Attard, M.D., Ph.D.

The Institute for Cancer Research - London, UK



Dr. Attard earned an M.D. degree from the University of Malta and a Ph.D. degree from the Institute of Cancer Research, London. He is currently a Senior Clinical Research Fellow at the Royal Marsden Hospital and the Institute for Cancer Research.

Inhibition of CYP17 by abiraterone has promising anti-tumor activity in advanced prostate cancer. This experimental medication blocks the production of the gasoline that fuels cancerous tumor growth. Nonetheless, 50 percent of chemotherapy-treated patients do not respond to abiraterone from the outset, and the majority of patients eventually develop acquired resistance. Circulating tumor cells, the small number of cells that break away from a solid mass and enter blood circulation, will be studied to identify a biomarker profile that predicts which patients might be sensitive to abiraterone and those that might become resistant.

Professor Johann de Bono, M.D., Ph.D., a preeminent medical oncologist at the Institute of Cancer Research in London and a leader in prostate cancer clinical trials, will be Dr. Attard's mentor.

Robbins Family - PCF Young Investigator

Tarek Bismar, M.D.

University of Calgary - Canada



Dr. Bismar earned an M.D. degree from the University of Damascus and then performed two fellowships in surgical and genitourinary pathology at Wayne State University and Harvard Medical School-Brigham and Women's Hospital. He is currently an Associate Professor of Pathology at the University of Calgary.

A specific fusion of pieces of two chromosomes is present in 50 percent of prostate cancers and is thought to drive the disease. In addition, a normal protein named PTEN suppresses tumor development unless genetically altered as is the case in many advanced prostate cancer cases. Dr. Bismar proposes to study both of these changes in model systems in an attempt to discover how together they deregulate the control of growth and survival that result in prostate cancer.

Peter Forsyth, M.D., an accomplished physician-scientist in molecular biology, will provide mentorship for Dr. Bismar.

Peter and Laurie Grauer - PCF Young Investigator

Steve Cho, M.D.

Johns Hopkins University - Baltimore, Maryland



Dr. Cho earned a B.S. degree in Molecular Biology from Johns Hopkins University and an M.D. degree from NYU School of Medicine. He completed a Fellowship in PET Imaging at Johns Hopkins University and is currently an Assistant Professor in the Department of Nuclear Medicine at Johns Hopkins University.

New methods to image prostate cancer at the microscopic level are urgently needed. Prostate specific membrane antigen (PSMA) is expressed on the surface of prostate cancer and represents a promising target for prostate cancer PET imaging. Lower molecular weight small molecule PET radiotracers should improve solid tumor detection. A novel small molecule radiotracer PET imaging agent has been developed to target PSMA with higher PET imaging resolution. In this program, Dr. Cho will begin to characterize this PET tracer in prostate cancer clinical trials for the objective of monitoring tumor volume changes during experimental treatment.

Martin Pomper, M.D., Ph.D., an eminent radiologist who specializes in nuclear medicine and molecular imaging of cancer at Johns Hopkins, will provide mentorship.

Kovler Family Foundation - PCF Young Investigator

Scott M. Dehm, Ph.D.

Masonic Cancer Center, University of Minnesota - Minneapolis, Minnesota



Dr. Dehm completed a B.S. and Ph.D. in Biochemistry at the University of Saskatchewan and has been a Postdoctoral Fellow working with Don Tindall at the Mayo Clinic. Dr. Tindall is a leading expert on the function of the androgen receptor. Dr. Dehm is currently an Assistant Professor at the University of Minnesota.

In the event that surgery or radiation does not curtail prostate cancer, locally recurrent or metastatic disease may be treated via a systemic blockade of the production or action of androgens. This so-called androgen ablation therapy specifically inhibits the androgen receptor (AR), a receptor that drives the proliferation and survival of prostate cancer. However, androgen ablation is not curative, and prostate cancer can invariably progress. Novel modes of AR inhibition are needed to study advanced prostate cancer. The goal of

this proposal is to create models that reflect how AR continues to cause proliferation and survival of prostate cancer even after androgen synthesis and activity are blocked.

Dr. Dehm's mentors at the Masonic Cancer Center, University of Minnesota will be Kenneth Koeneman, M.D., a urology specialist, and James McCarthy, Ph.D., who focuses on prostate cancer tumor biology and leads the Tumor Biology and Progression Research Program at the cancer center.

Gen-Probe Incorporated - PCF Young Investigator

Eleni Efstathiou, M.D., Ph.D.

The University of Texas M.D. Anderson Cancer Center - Houston, Texas



Dr. Efstathiou earned both M.D. and Ph.D. degrees at the University of Athens and is currently a medical oncology fellow at M.D. Anderson Cancer Center.


New experimental medications that shut off androgen (the fuel for prostate cancer) synthesis will likely become a standard of care for advanced prostate cancer in the next few years. The goal of Dr. Efstathiou's program is to measure androgen levels in the area of prostate cancer bone metastases to determine if androgens are undetectable, as is the case in tumor tissue from other sites, when total androgen suppressive medications are administered. It is thought that these studies will help determine which patients could benefit from or be resistant to these new medications.

Christopher Logothetis, M.D. will provide mentorship. Dr. Logothetis is a prostate cancer medical oncologist and heads the David H. Koch Prostate Cancer Center at M.D. Anderson. Dr. Logothetis has a long record of developing the careers of young investigators who have gone on to make important contributions to the field.

Michael Milken Scholar - PCF Young Investigator

Adam Feldman, M.D.

Massachusetts General Hospital Cancer Center - Boston, Massachusetts



Dr. Feldman earned a B.A. degree in the Biological Basis of Behavior from the University of Pennsylvania, an M.A. degree from Boston University School of Medicine, an M.D. degree from the University of Massachusetts, and he is currently earning his M.P.H. degree at Harvard School of Public Health. He completed training in urologic oncology at Massachusetts General Hospital and is currently an Assistant Professor of Urology and Surgery at the Massachusetts General Hospital.

Novel biomarkers for improved detection and prognosis of prostate cancer are needed. Intracellular, membrane-associated and secreted proteins are differentially expressed by prostate cancer cells as compared to benign prostate cells. Dr. Feldman proposes to discover these differentially expressed proteins in urine, a non-invasive practical biological fluid for biomarker discovery. The second goal of this project is to correlate biomarker findings with prostate cancer diagnosis, grade and pathologic stage.

Matthew Smith, M.D., Ph.D., of the MGH Cancer Center, is a world leader in prostate cancer clinical investigations for bone stability and improved survivorship in patients on hormonal therapy, and Bruce Zetter, Ph.D., a world-leading cancer biologist at Harvard Medical School, will serve as Dr. Feldman's co-mentors.

PCF Young Investigator

Steven Frank, M.D.

The University of Texas M.D. Anderson Cancer Center - Houston, Texas



Dr. Frank earned a B.S. degree in Nuclear Engineering from the United States Naval Nuclear Propulsion Program and an M.D. degree from Emory University. He completed a Fellowship in Radiation Oncology at M.D. Anderson Cancer Center and is currently an Assistant Professor of Radiation Oncology at M.D. Anderson Cancer Center.

Following prostate cancer treatment, men are often embarrassed if they become incontinent. Recent data reveals that up to 33 percent of men or approximately 73,000 men annually will be wearing diapers or pads for up to two years following their treatment. The goal of Dr. Frank's proposal is to eliminate incontinence by 2012 for men treated with brachytherapy through MRI image-guided radiation therapy. With accurate dose determination, cancer cure rates will increase and side effects will decrease translating into an improvement in quality of life following prostate cancer treatment.

David Swanson, M.D., will provide mentorship. He has a record of more than 32 years as a scholar at M.D. Anderson and has helped develop the careers of dozens of now well-established investigators.

The Joy and Jerry Monkarsh Family Foundation - PCF Young Investigator

Isil Guney, Ph.D.

Dana-Farber Cancer Institute - Boston, Massachusetts



Dr. Guney, originally from Ankara Turkey, received a B.S. in Biology from Xavier College of Louisiana and a Ph.D. in Molecular Biology from Brown University. She is currently a Postdoctoral Fellow at the Dana-Farber Cancer Institute.

Prostate cancers are initially dependent on androgens for survival and androgen-ablation therapies comprise the only effective treatment for metastatic disease. Eventually, however, prostate tumor cells acquire the capacity to survive and proliferate at exceedingly low levels of circulating androgens, and such hormone therapy-resistant prostate cancers are incurable. A thorough understanding of the molecular events that promote the development of hormone resistance in prostate cancer is necessary for the design of effective therapies for patients with hormone resistant disease. The goal of Dr. Guney's project is to identify molecules that are suitable for development as therapeutic targets in advanced prostate cancers.

Dr. Guney's Mentor is William C. Hahn, M.D., Ph.D., a leading molecular oncologist and physician-scientist. Dr. Hahn is an expert in cell and molecular biology of prostate cancer genomics who made major contributions to prostate cancer research at an early age.

Neubauer Family Foundation - PCF Young Investigator

Thomas Guzzo, M.D.

University of Pennsylvania - Philadelphia, Pennsylvania



Dr. Guzzo earned a B.S. in Biology from Ursinus College and an M.D. from Temple University School of Medicine. He is currently a Urologic Oncology Fellow and clinical instructor at Johns Hopkins.

Dr. Guzzo is a urologist completing his fellowship program at Johns Hopkins. He is also a Neubauer Family-PCF Young Investigator at the University of Pennsylvania where he will be creating a prostate cancer translational research unit within the urology division. Dr. Guzzo will focus on clinical outcomes to improve surgical results for men diagnosed with early prostate cancer that include novel approaches to reducing morbidity from surgery.

Dr. Guzzo will be mentored by Alan Wein, M.D. Dr. Wein is head of the Division of Urology at the University of Pennsylvania School of Medicine and Chief of Urology at the Hospital of the University of Pennsylvania. He is also the editor of the leading textbook in urology.

DeFeo Family - PCF Young Investigator

Andrea Harzstark, M.D.

University of California at San Francisco



Dr. Harzstark earned a B.S. degree in Biological Sciences and an M.D. degree from Stanford University. She is currently a Fellow in Hematology and Oncology at UCSF.

Immunotherapy offers the potential to stimulate a prostate cancer patient's immune response to kill a growing tumor. Unfortunately, cancer cells are very weak vaccine agents and require other co-therapeutic strategies to be effective. Dr. Harzstark proposes to enhance the immune response to prostate cancer with a variety of approaches that might result in elimination of tumors.

Dr. Eric Small will serve as mentor. He is a leader and frequently published expert in the field of prostate cancer immunotherapy clinical investigation, the research area upon which Dr. Harzstark will focus.

PCF Young Investigator

Sarah Holt, Ph.D.

Fred Hutchinson Cancer Research Center - Seattle, Washington



Dr. Holt earned a BA in Biology from Skidmore College, an M.S. in Public Health from the University of Colorado and a Ph.D. in Epidemiology from the University of Washington. She is currently a Senior Postdoctoral Research Fellow at the Fred Hutchinson Cancer Research Center.

Carcinogenic effects of estrogen on the prostate have been demonstrated in laboratory models. Furthermore, there is a current resurgence of interest in using synthetic estrogens to treat patients with advanced prostate cancer. Dr. Holt plans to study genetic alterations in genes responsible for estrogen sensitivity and metabolism in the prostate of approximately 1,457 prostate cancer patients compared to 1,351 control subjects without prostate cancer. Results should help identify patients with increased risk for primary prostate cancer and those who might develop a more aggressive form of the disease.

Dr. Janet Stanford, an internationally-recognized prostate cancer geneticist and population scientist, will provide mentorship.

Michael Milken Scholar - PCF Young Investigator

Lorelei A. Mucci, Sc.D., M.P.H.

Harvard School of Public Health - Boston, Massachusetts



Dr. Mucci earned a B.S. in Biology at Tufts University, an M.P.H. in Epidemiology from Boston University, and an Sc.D. in Epidemiology from the Harvard School of Public Health. She is currently an Assistant Professor in Medicine and Epidemiology at The Channing Laboratory, Brigham and Women's Hospital.

A recent finding in prostate cancer biology is the existence of specific fusions of chromosomes in disparate regions of a patient's genome. These fusions give rise to expression of molecules with strong cancer-causing properties. Emerging data suggest men with tumors that lack the fusion have an improved prognosis compared to men with fusion-positive prostate cancer. This scientist will study 1,500 prostate cancer patients to understand the relationship of the gene fusions to hormonal balance, energy balance, and healthy weight. The impact of these physiological properties on patient survival will be determined.

Dr. Mucci will be co-mentored by Philip Kantoff, M.D. (Dana-Farber Cancer Institute) and Meir Stampfer, M.D., M.P.H. (Harvard School of Public Health). Drs. Kantoff and Stampfer are among the most frequently cited prostate cancer researchers in the world for high-impact contributions.

William L. Edwards - PCF Young Investigator Award

Mark Pomerantz, M.D.

Dana-Farber Cancer Institute - Boston, Massachusetts



Dr. Pomerantz earned a B.S. degree in American Studies from Yale University and an M.D. degree from Stanford University. He completed Medical Oncology Fellowship at the Dana-Farber Cancer Institute and is currently an Instructor in Medical Oncology at the Dana-Farber Cancer Institute.

During the past two years, genomic scans have identified the genetic basis of prostate cancer risk. In his project, Dr. Pomerantz will perform research to determine the molecular basis of increased prostate cancer risk in individuals that possess the genomic alterations. Understanding these mechanisms of risk may lead to new targets to inhibit the progression of prostate cancer.

Philip Kantoff, M.D. an expert translational and clinical prostate cancer researcher and leader of the NCI's prostate cancer Special Programs of Research Excellence (SPOR) at

Harvard, and Matthew Freedman, M.D., an experienced genomics researcher, will co-mentor Dr. Pomerantz.

Durden Foundation - PCF Young Investigator

Ganesh Raj, M.D.

UT Southwestern Medical Center - Dallas, Texas



Dr. Raj earned a B.S. degree in Biology from Johns Hopkins University and an M.D. degree from Jefferson Medical College. He trained in urologic oncology at Memorial Sloan-Kettering Cancer Center and is currently an Assistant Professor of Urology at the UT Southwestern Medical Center in Dallas.

The androgen receptor (AR) system plays a central role in prostate cancer and represents a critical target for novel drugs in the treatment for this disease. Targeting specific genes is now possible, but the delivery of these new inhibitors to their targets is difficult. The focus of Dr. Raj's proposal is to refine a system that will be both an MR imaging agent and a drug delivery vehicle for gene-targeted inhibitors. Specific gene targets are the AR and AR-associated molecules.

Jer-Tsong Hsieh, Ph.D., a leader in human prostate cancer molecular biology and a professor of urology at UT Southwestern, will provide mentorship for Dr. Raj.

PCF Young Investigator Award

William L. Redmond, Ph.D.

Providence Portland Medical Center - Portland, Oregon



Dr. Redmond earned a B.S. in Biology from the University of California – Davis and a Ph.D. in immunology from the Scripps Research Institute. He is currently a Postdoctoral Fellow at the Providence Portland Medical Center.

Recent clinical trials have demonstrated that immunotherapy-based treatments hold promise for prostate cancer therapy, including tumor-specific vaccines and immuno-enhancing agents. Dr. Redmond proposes to further enhance cancer vaccine therapy by the discovery and development of new classes of immuno-stimulators.

His mentor, Dr. Andrew Weinberg, is a leading human tumor immunologist with a strong track record of mentoring young biomedical researchers towards independent careers.

Anonymous Donor - PCF Young Investigator

Nima Sharifi, M.D.

UT Southwestern Medical Center - Dallas, Texas



Dr. Sharifi earned a B.S. in Biology from Virginia Polytechnic Institute and an M.D. from the University of Pittsburgh. Following Internal Medicine training at Yale University, Dr. Sharifi completed a Fellowship in Medical Oncology at the NCI. He is currently an Assistant Professor of Medicine at the UT Southwestern Medical Center in Dallas.

Metastatic prostate cancer is treated with androgen deprivation therapy that reduces testosterone, the "gasoline" that fuels the growth and progression of prostate cancer. Despite frequent responses, tumors almost always recur with subsequent activation of the androgen receptor (AR), the target for testosterone. Therefore, therapies that down-regulate AR using novel mechanisms, have a tremendous potential to introduce new treatments and improve the outlook for prostate cancer patients. The first objective of this proposal is to determine if the down regulation of certain anti-oxidants will over-activate AR function. The second objective of this proposal is to use a novel method to find better tumor markers that herald prostate cancer progression in state of poor anti-oxidation.

Dr. Sharifi will be mentored by Thomas Kodadek, Ph.D., chief of the division of translational medicine at UT Southwestern Medical Center. He is an eminent biochemist who has made significant contributions to fundamental cancer research.

The LeFrak Family - PCF Young Investigator

Scott Tagawa, M.D.

Weill Cornell Medical College - New York, New York



Dr. Tagawa earned a B.S. in Biology from Georgetown University and an M.D. degree from USC where he completed a Fellowship in Hematology and Oncology. He is currently an Assistant Professor of Medicine and Urology at the Weill Cornell Medical College.

J591 is a monoclonal antibody against prostate specific membrane antigen (PSMA), a molecule on the surface of prostate cancer cells. Studies using J591 linked to radioisotopes (radioimmunotherapy, RIT) have demonstrated safety and efficacy as well as the ability to target known sites of disease in metastatic prostate cancer. Dr. Tagawa will continue clinical investigations of J591 in patients with advanced prostate cancer to determine the dosage and optimal administration schedule required to effectively treat the disease.

Neil Bander, M.D., a world leader in urologic oncology translational research and inventor of the J591 monoclonal antibody, will provide mentorship.

For the benefit of the more than two million American men and their families who are currently battling prostate cancer, we are pleased to be backing our PCF *Young Investigators* and their talents with the support of their patrons listed above. We will follow their progress, and report back to you on their discoveries—as they make them.

-PCF-
